

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



武夷药业  
Wuyi Pharmaceutical

**WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED**

**武夷國際藥業有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1889)

**DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2015**

**AND  
SUSPENSION OF TRADING**

**Delay in Publication of Annual Results Announcement for the year ended 31 December 2015**

The Board announces that as additional time is required by the Company to perform and complete certain essential audit procedures as requested by the independent auditor of the Company, Crowe Horwath (HK) CPA Limited, so as to enable them to complete the audit of the 2015 Audited Results, the Company were not able to publish the Results Announcement on or before 31 March 2016. The Board expects the Results Announcement will be published on or around 8 April 2016.

**Suspension of Trading**

At the request of the Company, trading in the Company's shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2016 pending the publication of the Results Announcement.

This announcement is made by Wuyi International Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.49(3) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

**Delay in Publication of Annual Results Announcement for the year ended 31 December 2015**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces

that as additional time is required by the Company to perform and complete certain essential audit procedures in i) trade receivables and other payables and ii) impairment loss and recoverability assessment on deposits paid for acquisition of a subsidiary as requested by the independent auditor of the Company, Crowe Horwath (HK) CPA Limited, so as to enable them to complete the audit of the consolidated results of the Group for the year ended 31 December 2015 (the “**2015 Audited Results**”), the Company were not able to publish the announcement in respect of the 2015 Audited Results (the “**Results Announcement**”) on or before 31 March 2016. The Board expects the Results Announcement will be published on or around 8 April 2016.

Pursuant to Rule 13.49(1) of the Listing of Rules, the Company is required to publish the Results Announcement on or before 31 March 2016. The Board acknowledges that the delay in the publication of the Results Announcement constituted a non-compliance of Rule 13.49(1) of the Listing Rules.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to publish its preliminary results in accordance with the requirements of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the independent auditor (so far as the information is available). After due and careful consideration, the Board formed the view that as the Results Announcement containing the 2015 Audited Results is expected to be published shortly on or around 8 April 2016, it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2015 for the time being as it may be misleading and confusing to shareholders and potential investors.

### **Suspension of Trading**

At the request of the Company, trading in the Company’s shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2016 pending the publication of the Results Announcement for the year ended 31 December 2015.

By Order of the Board  
**Wuyi International Pharmaceutical Company Limited**  
**Lin Ou Wen**  
*Chairman and Chief Executive Officer*

Hong Kong, 1 April 2016

*As at the date of this announcement, the Board comprises 3 executive Directors, namely Mr. Lin Ou Wen (Chairman), Mr. Lin Qing Ping and Mr. Xu Chao Hui, 2 non-executive Directors, namely Mr. Tang Bin and Mr. John Yang Wang, and 3 independent non-executive Directors, namely Mr. Liu Jun, Mr. Lam Yat Cheong and Mr. Du Jian.*